BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/15/2025 8:37:54 AM | Browse: 188 | Download: 70
 |
Received |
|
2025-03-07 10:07 |
|
Peer-Review Started |
|
2025-03-07 10:08 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2025-04-02 10:53 |
|
Revised |
|
2025-04-09 14:26 |
|
Second Decision |
|
2025-04-18 02:42 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2025-04-18 06:45 |
|
Articles in Press |
|
2025-04-18 06:45 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-09-02 06:26 |
|
Publish the Manuscript Online |
|
2025-09-15 08:37 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Postoperative immune checkpoint inhibitors plus anti-angiogenesis for hepatitis B virus-associated hepatocellular carcinoma: Analyzing the evidence and future prospects
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Arunkumar Krishnan and Diptasree Mukherjee |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Arunkumar Krishnan, MD, Department of Supportive Oncology, Atrium Health Levine Cancer, 1021 Morehead Medical Drive, Charlotte, NC 28204, United States. dr.arunkumar.krishnan@gmail.com |
| Key Words |
Adverse events; Biomarkers; Bias; Confounders; Hepatitis B virus; Hepatocellular carcinoma; Postoperative combined therapy; Immunotherapy; Follow-up |
| Core Tip |
A recent study by Lu et al examined postoperative combined therapy (PCT) for hepatitis B virus-associated hepatocellular carcinoma (HBV-HCC). While the findings provide important insights, it is essential to acknowledge several significant limitations. These include the potential for selection bias, a small sample size, and an insufficient focus on monitoring hepatitis B virus reactivation in detail. Future research should prioritize prospective, randomized controlled trials and adopt biomarker-driven approaches to advance the knowledge of the efficacy and safety of PCT. Moreover, extending follow-up periods and fostering global collaboration could enhance treatment outcomes and more effective patient care strategies in managing HBV-HCC. |
| Publish Date |
2025-09-15 08:37 |
| Citation |
<p>Krishnan A, Mukherjee D. Postoperative immune checkpoint inhibitors plus anti-angiogenesis for hepatitis B virus-associated hepatocellular carcinoma: Analyzing the evidence and future prospects. <i>World J Gastrointest Oncol</i> 2025; 17(9): 106801</p> |
| URL |
https://www.wjgnet.com/1948-5204/full/v17/i9/106801.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v17.i9.106801 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
